Comparison of Efficacy and Safety of Tenofovir and Entecavir in Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis

Weixia Ke*, Li Liu*, Chi Zhang, Xiaohua Ye, Yanhui Gao, Shudong Zhou, Yi Yang*  
Department of Epidemiology and Biostatistics and Guangdong Key Lab of Molecular Epidemiology, School of Public Health, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China

Abstract

Objective: Tenofovir (TDF) and entecavir (ETV) are both potent antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection. Multiple studies have compared efficacy and safety of these two agents, but yielded inconsistent results. Hence, we conducted a meta-analysis to discern comparative efficacy and safety.

Methods: Published data relevant to a comparison of TDF and ETV used in HBV were included. HBV DNA suppression rate, ALT normalization rate, and HBeAg seroconversion rate at 24 weeks and 48 weeks were reviewed. Drug safety profiles and resistance were also discussed.

Results: Seven articles met entry criteria. Four and six articles included data for 24 and 48-week HBV DNA suppression rates, respectively, and no significant differences for the rates between the two drugs were found in chronic HBV patients (TDF vs. ETV: relative risk [RR] = 1.10, 95% CI = 0.91–1.33 and RR = 1.07, 95% CI = 0.99–1.17 for 24 weeks and 48 weeks, respectively). For the ALT normalization rate (three studies for 24 weeks, four articles for 48 weeks) and HBeAg seroconversion rate (two and four studies for 24 weeks and 48 weeks, respectively), no difference was observed between TDF and ETV. Additionally, no significant distinction in short term safety was found for CHB patients.

Conclusions: TDF and ETV are similarly effective and safe in chronic HBV patients after 24 weeks and 48 weeks of anti-viral therapy. Nevertheless, the long-term efficacy and safety of TDF and ETV should be monitored in prolonged therapy.

Citation: Ke W, Liu L, Zhang C, Ye X, Gao Y, et al. (2014) Comparison of Efficacy and Safety of Tenofovir and Entecavir in Chronic Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis. PLoS ONE 9(6): e98865. doi:10.1371/journal.pone.0098865

Editor: Xiaoping Miao, MOE Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, China

Received February 14, 2014; Accepted May 7, 2014; Published June 6, 2014

Copyright: © 2014 Ke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by Program for Guangdong Medical research Foundation (Grant No. B2012176), National Natural Science Foundation of China (NSFC-81302493) and Foundation for Distinguished Young Talents in Higher Education of Guangdong (Grant No. 2012LYM_0082). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: yangyigz@163.com
† These authors contributed equally to this work.

Introduction

Chronic hepatitis B virus (HBV) infection remains a serious global health concern. Currently, approximately 2 billion people have been infected with HBV, and over 350 million are suffering from chronic hepatitis B (CHB) worldwide [1]. Cirrhosis, liver failure, and/or hepatocellular carcinoma (HCC) are expected to develop in 15%–40% of patients with CHB without appropriate treatment [2], and approximately 1 million patients die annually of cirrhosis, liver failure, and HCC as a result of chronic HBV infection [3]. Therefore, the main goal of treatment of chronic infection is to effectively suppress viral replication, preventing liver disease, progression to cirrhosis, liver failure, and HCC [4–6]. Effective antiviral therapy via sustained HBV DNA suppression has become a priority research focus for chronic infection [4–6]. Available antiviral drugs include immunomodulatory drugs (interferon-alpha and pegylated interferon-alpha) and nucleotide analogue (NAs) polymerase inhibitors (lamivudine [LAM], adefovir [ADV], entecavir [ETV], telbivudine [LdT], and tenofovir [TDF]). Since interferons are expensive, require parental administration, and cause side effects, oral nucleos(t)ide analogues are preferred [7]. Although LAM, ADV, and LdT are approved for the treatment of chronic HBV infection, high rate of resistance has plagued therapeutic use. At present, the two first line nucleoside/nucleotides are ETV and TDF. ETV is a potent antiviral that effectively suppresses HBV DNA replication. It has a high genetic barrier for resistance in HBeAg-positive and HBeAg-negative patients [8–9] with a cumulative resistance probability of 1.2% after 5 years of treatment [10]. However, in lamivudine-refractory patients, the cumulative probability of genotypic ETV resistance developing over 5 years is 51% [11]. TDF is newer and considered a higher efficiency antiviral drug with a high genetic barrier. To date, no evidence exists to show development of resistance to TDF up to 144 weeks of therapy [12]. Moreover, TDF has been demonstrated to be effective in patients with both adefovir and lamivudine failure [13]. TDF is more effective than ETV to...
achieve rapid viral suppression in HBeAg-positive chronic HBV patients [14]. Additionally, the Bayesian meta-analysis by Woo et al. highlighted TDF as the more effective agent for HBeAg-negative patients during the first year of therapeutic intervention [15]. TDF is proposed to be superior to ETV for treating chronic HBV; however, a more promising result was shown by multiple studies claiming that both are similar in both efficacy and safety [16–21]. Due to the small sample sizes of past studies and subsequent limited data for comparing the two drugs, a more definitive conclusion is lacking. Herein, we conducted this meta-analysis by integrating published drug-based data to compare efficacy and safety of TDF and ETV and ultimately provide evidence for clinical decisions.

Materials and Methods

Literature search

PubMed/Medline, Web of Science, EMBASE, The Wiley Online library, CNKI, WANFANG database, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Review databases were searched for relevant articles through June 30,2013 without language limitation. The search strategy was based on a combination of the key words “chronic hepatitis B virus or HBV or CHB”, “entecavir or ETV”, “tenofovir or TDF”. Reference lists from retrieved documents were also scanned. Two reviewers independently screened citations and articles of each article (Wei-xia Ke and Chi Zhang).

Inclusion and exclusion criteria

The following inclusion criteria were used for this meta-analysis: (1) randomized and non-randomized control trials (included cohort or case-control studies), (2) study population consisting of patients with chronic HBV infection, and (3) intervention therapies of entecavir versus tenofovir monotherapy. The following types of studies were excluded: (1) studies of patients who were co-infected with HIV, HCV, or HDV; (2) studies of patients who adopted combination therapy or sequential therapy, (3) studies of individuals who used immunomodulatory drugs or other nucleotide analogues within the preceding 6 months, (4) studies not reporting any efficacy measures or not conveying sufficient statistical information, and (5) studies not including either tenofovir or entecavir.

Efficacy measures

Efficacy was considered for patients 24 and 48 weeks post therapy by considering the following: HBV-DNA level (<400 copies/ml), ALT normalization rate (<40 IU/ml), HBeAg seroconversion rate (HBeAg loss and the appearance of HBe antibody), and drug safety (adverse events, laboratory abnormalities, deaths, tolerability, etc).

Data extraction

Two authors extracted data independently and recorded the following for each publication: the first author’s name, published year, country of study, time of study (start date and end date), number of patients, details of study design, patient characteristics (average age, gender, etc), treatment doses and duration, and outcome measures performed (described earlier). Where eligible, the authors of articles with insufficient data were contacted. If they did not provide data after contact, those articles were excluded from our meta-analysis.

Study quality

The two reviewers also assessed methodological quality based on following criteria: (1) Randomized controlled trials (RCTs) were assessed using the QUOROM guidelines and the Jadad scale [22]; (2) non-RCTs must have met the case matched by the patient’s baseline data; (3) selected studies had defined inclusion and exclusion criteria for the study population and a clear definition of treatment responses. Reviewers resolved discrepancies through discussion.

Statistical analysis

Pooled rates for DNA suppression, ALT normalization, and HBeAg seroconversion were estimated using the inverse variance method. Relative risks (RRs) and 95% confidence intervals (CIs) as metrics of effect size were re-calculated for TDF versus ETV (as reference) in DNA suppression, ALT normalization, and HBeAg seroconversion rates. Inter-study heterogeneity was evaluated by the χ²-based Cochran’s Q statistic test and I² metric, with significance set at P<0.10 or I²>50%. In the absence of significant heterogeneity, the fixed-effect model using Mantel-Haenszel method was applied to combine results [23]. In other cases, the random-effect method, using DerSimonian and Laird methods was applied [24]. Sensitivity analysis assessed whether a single study significantly affected overall estimates by sequentially removing studies. The Begg’s rank correlation test and Egger’s linear regression test were conducted for assessing publication biases. All statistical analyses were carried out in STATA V11.0, and all P values are two-tailed with a significant level at 0.05. This meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement (Checklist S1) [25].

Results

Search results and study characteristics

We identified 885 citations via electronic searches (Fig. 1). Seven were selected describing treatment of chronic HBV infection involving 844 patients (378 treated with TDF monotherapy and 466 treated with ETV monotherapy). Of these studies, two were RCTs [16–17], four were cohort studies [18–21], and one was a case-cohort study [14]. The detailed information of included studies is summarized in Table 1.

Study quality

Two manuscripts [16–17] were RCTs. One received Jadad scores of 3 and the other 3 (Table 2). For non-RCTs, all were well-matched based on baseline characteristics and clear definition of treatment response. With exceptions of Gao et al. [14] and Kurdas et al. [20] non-RCTs had defined inclusion and exclusion criteria for patients (Table 3).

HBV DNA suppression rate

For four studies evaluating patients post 24 weeks of therapy [14,17,20,21], the pooled HBV DNA suppression rates were 50% (95%CI = 25%–74%) and 46% (95%CI = 24%–68%) for TDF and ETV, respectively. No significant heterogeneity existed across studies (P for heterogeneity = 0.63; I² = 0%). In the fixed-effect model, no significantly difference was determined between TDF and ETV treatment groups in the HBV DNA suppression rate through 24 weeks of treatment (RR = 1.10, 95% CI = 0.91–1.33; Fig.2). Six studies compared HBV DNA suppression rates after 48 weeks of therapy (Fig.3), which were also similar for TDF (80%, 95%CI = 71%–90%) and ETV (76%, 95%CI = 63%–88%). No significant heterogeneity was observed (P=0.59, I² = 0%), and
no significant difference was also observed in that rate after 48 weeks treatment between the two treatment groups (RR = 1.07, 95%CI = 0.99–1.17). The statistic power for 24 and 48 weeks HBV DNA suppression rates were 92.08% and 85.03%, respectively.

ALT normalization rate

Pooled ALT normalization rates from three studies were 75% (95%CI = 59%–91%) and 76%(95%CI = 68%–83%) that included TDF and ETV groups 24 weeks post treatment, respectively. No significant difference between TDF and ETV for ALT normalization rate was calculated for 24 weeks post treatment (RR = 0.89, 95% CI = 0.77–1.04) (Fig.4). Four studies involved comparing ALT normalization rates after 48 weeks of therapy (Fig.5). The pooled rate for the TDF group (74%, 95%CI = 62%–86%) was similar to that of the ETV group (81.0%, 95%CI = 76%–86%). No significant difference was calculated after 48 weeks treatment between the two drugs (RR = 0.91, 95%CI = 0.83–1.01; P for heterogeneity= 0.26, $I^2 = 26\%$).

HBeAg seroconversion rate

Two studies involved HBeAg seroconversion rates 24 weeks post treatment (Fig.6). Heterogeneity was found to be a concern (P for heterogeneity = 0.53; $I^2 = 0\%$). The results of the two studies indicated that the pooled HBeAg seroconversion rate for the TDF group was 28% (95%CI = −10%–65%) and the ETV group response rate was 29% (95%CI = −12%–59%). The pooled relative risk was 0.86 (95%CI = 0.45–1.66), suggesting no significant difference. Four studies were included to compare HBeAg seroconversion rates at 48 weeks post treatment (Fig.7). The pooled rates of 48 weeks post therapy were similar between TDF (16%, 95%CI = 0%–32%) and ETV (10%, 95%CI = 0%–20%). Heterogeneity was not found (P for heterogeneity = 0.39; $I^2 = 1\%$), and a difference between the two groups was not significant (RR = 1.09, 95%CI = 0.57–2.11).

Tolerability and Safety of tenofovir and entecavir

Liaw et al. [16] found no significant differences between the TDF and ETV treatment groups for both co-primary safety endpoints (tolerability failures and confirmed changes in renal parameters) in decompensated CHB patients. Most adverse events (AEs) and laboratory abnormalities were consistent with decompensated cirrhosis, with few AEs related to these two agents. Sriprayoon et al. [17] reported no serious adverse events and no drop in renal function related to both agents. Additionally, for patients with HBV-related cirrhosis, Koklu et al. [18] concluded that TDF and ETV were similarly safe agents for long-term use. Furthermore, Dogan et al. reported that both drugs were well tolerated with minimal side effects. No significant increase in creatinine was detected. [19]

Virological breakthrough and resistance

Two studies referred to virological breakthrough or resistance. In the resistance surveillance by Liaw et al. [16], 13 patients (eight
| Study       | Location    | Ethnicity          | Study design | Sample size | Gender | Age (yrs) | Baseline HBV DNA level | HBeAg (+)/(−) Status |
|------------|-------------|--------------------|--------------|-------------|--------|-----------|------------------------|----------------------|
| Liaw [16]  | Worldwide   | Asian/White/Other  | RCTs         | 45          | 22     | 54 / 13  | ≥10^5 copies/ml         | 14 / 31 / 7 / 15     |
| Sriprayoon [17] | NA         | NA                 | RCTs         | 100         | 100    | NA / NA  | >2,000 IU/ml           | 52 / 48 / 54 / 46   |
| Koklu [18]  | Turkey      | NA                 | Cohort       | 72          | 77     | 114 / 35 | Mean (SD): 54.2(10.5) vs. 52.4(11.2) | Naïve, Cirrhosis |
| Dogan [19]  | Turkey      | NA                 | Cohort       | 65          | 29     | 58 / 36  | Mean (SD): 54.2(10.5) vs. 52.4(11.2) | Naïve, Cirrhosis |
| Kursad [20] | Caucasus    | Caucasian          | Cohort       | 20          | 24     | 31 / 13  | Mean (SD): 6 log copies/ml | 6 / 14 / 5 / 19     |
| Jayakumar [21] | India      | NA                 | Cohort       | 19          | 20     | 35 / 4   | Mean (SD): 6 log copies/ml | 6 / 14 / 5 / 19     |
| Gao [14]    | U.S.        | NA                 | Case Cohort  | 57          | 194    | 96 / 155 | Mean: 41.6 vs. 43.2     | 37 / 20 / 120 / 74  |

Note: NA, not available; TDF, tenofovir; ETV, entecavir; SD, Standard Deviation; RCTs, randomized controlled trials; CHB, chronic hepatitis B.
doi:10.1371/journal.pone.0098865.t001

| Study       | Adequate sequence generation | Allocation concealment | Blinding | Incomplete outcome data addressed | Free of selective reporting | Free of other bias | Jadad |
|------------|------------------------------|------------------------|----------|----------------------------------|-----------------------------|-------------------|-------|
| Liaw [16]  | Yes                          | Yes                    | Yes      | Yes                              | Yes                         | Yes               | 5     |
| Sriprayoon [17] | Unclear            | Unclear                | Unclear  | Unclear                          | Unclear                     | Unclear           | 3     |

doi:10.1371/journal.pone.0098865.t002
TDF, two emtricitabine [FTC]/TDF, and three ETV) qualified for genotypic testing based on viremia through 48 weeks, and no patient developed resistance to any study drug throughout the 48 weeks. Two of three ETV patients with baseline lamivudine resistance switched to open-label FTC/TDF due to insufficient viral suppression at week 24 (all three had HBV DNA < 400 copies/ml at week 48). Koklu et al. [18] reported that two of 77 patients switched from ETV to TDF at 24th and 40th month of treatment, respectively, because of virological breakthrough. No evidence for viral resistance to TDF was identified in these studies.

Sensitivity analysis
Sensitivity analysis was performed via the random-effect model only for the 48 weeks HBV DNA suppression rate (the rest of indicators confined to limited articles are not concerned). Pooled RRs were similar before and after removal of each study, and no single study significantly altered the pooled RRs, suggesting the robust stability of these results (Table 4).

Publication bias
Funnel plot shapes revealed no evidence of asymmetry for all efficacy measures. Begg's or Egger's test also showed no publication bias (all P values > 0.05).

Discussion
Entecavir (ETV) and tenofovir (TDF), two nucleotide analogs (NAs) are the most potent antiviral drugs for HBV infection [4–6]. Entecavir is a carboxylic analogue of guanosine that undergoes intracellular phosphorylation to its active 5’ triphosphate metabolite. This form competes with the natural substrate deoxyguanosine triphosphate to inhibit HBV DNA polymerase, which is essential for viral replication [26]. Likewise, Tenofovir undergoes phosphorylation to mimic deoxyguanosine 5’-triphosphate. Once incorporated into the HBV DNA polymerase reaction, it functions as a chain terminator. ETV and TDF share a similar mechanism to suppress HBV DNA – they both compete with native substrates for polymerase binding to terminate transcription [27]. Rates of HBV DNA suppression for TDF range from 68% to 90% and ETV from 61% to 92% after 48 weeks of therapy [28–32]. In our meta-analysis, results for pooled HBV DNA suppression rates for TDF and ETV were similar: 48 weeks post treatment were 80% and 76%, respectively, and 24 weeks post treatment were 50% and 46%, respectively. Furthermore, no significant differences in rates were seen between the TDF and ETV treatment groups (24 weeks: RR = 1.10 95% CI = 0.91–1.33; 48 weeks: RR = 1.07 95% CI = 0.99–1.17), suggesting similar efficacy for TDF and ETV in suppressing HBV DNA.

ALT level is a biomarker reflecting host immune response against virus-infected hepatocytes. ALT normalization usually follows a virological response and indicates cessation of ongoing liver injury. In our meta-analysis, pooled ALT normalization rate for ETV was 76% and 75% for TDF. After 48 weeks of therapy, the pooled ALT normalization rate for ETV (81%) was similar to TDF (74%), indicating that both normalize ALT levels (24 weeks: RR = 0.89, 95% CI = 0.77–1.04; 48 weeks: RR = 0.91, 95%CI = 0.83–1.01).

Additionally, pooled HBcAg seroconversion for TDF was similar to the ETV group (24 weeks: 28% vs. 29%, RR = 0.86, 95% CI = 0.45–1.66; 48 weeks: 16% vs. 10%, RR = 1.09, 95% CI = 0.57–2.11). TDF and ETV do not greatly influence HBcAg seroconversion for HBV patients. Compared to pegylated interferon that enhances the host immune system to mount defense against HBV, oral NA therapy (including TDF and ETV) confers lower HBcAg seroconversion rates at the end a year of treatment [33]. Furthermore, spontaneous seroconversion from HBcAg to anti-HBcAb during chronic hepatitis B is also immunologically mediated [3]. Therefore, it is plausible that TDF and ETV may have a marginal host immune system impact, yielding lower rates of seroconversion. This has yet to be supported.

Although oral nucleoside analogues, including ETV and TDF, are known to have relatively few side effects and are generally tolerated more than interferon, it is necessary to monitor long-
Figure 3. Forest plot for HBV DNA suppression rates 48 weeks post therapy.
doi:10.1371/journal.pone.0098865.g003

Figure 4. Forest plot for ALT normalization rates 24 weeks post therapy.
doi:10.1371/journal.pone.0098865.g004

Figure 5. Forest plot for ALT normalization rates 48 weeks post therapy.
doi:10.1371/journal.pone.0098865.g005

Figure 6. Forest plot for HBeAg seroconversion rates 24 weeks post therapy.
doi:10.1371/journal.pone.0098865.g006
term potential risks. ETV is classified as a category C drug and as it is associated with potential risk of fetal injury, it should be avoided during the first trimester of pregnancy [34]. TDF is eliminated mainly through nephrotoxicity [35], so all patients receiving TDF, creatinine clearance must be determined before and during therapy. Renal failure was not observed in Phase III clinical trials of TDF in patients with HBV monoinfection after up to 192 weeks of treatment [36–37]. Observation periods to date been too short, resulting in insufficient data to appraise whether difference exists for safety profiles of ETV and TDF.

To achieve long-term antiviral success, a high barrier to resistance is also critical for antiviral agents [38]. TDF and ETV both present low rates of resistance and have had success in patients failing to previous NA therapy [39–40]. Although resistance to ETV requires three mutations, pre-existing LAM resistance-associated mutations provide some foundation for ETV resistance [41–42] since resistance to ETV shares two common mutations (rtM204V and rtL180M) with LAM. In patients with LAM-resistant HBV, a high 6-year resistance rate of 57% has been suggested for ETV [10,43]. Undetectable HBV DNA is not always achieved and virological breakthrough has occurred with ETV [44]. Additionally, it has been reported that sequential monotherapy of ETV can further promote multidrug resistant mutations [45]. Therefore, ETV monotherapy no longer be considered an optimal first-line therapy against LAM-resistant HBV. Moreover, TDF is a beneficial alternative for LAM failure patients, despite an incomplete resistance profile [13,38,39].

Some limitations merit consideration. In our study, major included studies were non-RCTs (5 of 7 studies). It has been reported that some factors, geographic, ethnic or disease status (CHB or cirrhosis) differences are possibly associated with agent efficacy. However, considering limited studies numbers for each factor, further analysis was restricted. Besides, due to the limited number of studies, analysis for some effect indicators might be underpowered (The power for 24 and 48 weeks HBV DNA suppression rates were 92.08% and 85.03%, respectively. The rest of indicators' powers are less than 80%). Although current related studies have shown TDF may be used as an alternative agent against HBV infection in drug safety and resistance, this study results still need more studies and reasonable statistic methods used to explore safety and tolerability of these drugs.

Our meta-analysis indicates that ETV and TDF are comparable in efficacy and safety to sustain HBV DNA suppression with limited side effects. However, in considering limited efficacy of ETV in patients with LAM resistance, TDF is an alternative agent against HBV infection. Nonetheless, long-term efficacy and safety of TDF and ETV should be monitored in prolonged therapy in well-designed prospective studies with large sample sizes.

**Supporting Information**

**Checklist S1** PRISMA Checklist. (DOC)

**Author Contributions**

Conceived and designed the experiments: YY WXK. Performed the experiments: WXK CZ. Analyzed the data: WXK CZ. Contributed reagents/materials/analysis tools: XHY YHG SDZ YY. Wrote the paper: WXK LL.
References

1. Saiioleas M, Lygidakis NJ, Mantu C (2007) Hepatitis B today. Hepatogastroenterology 54: 549–8.
2. Laruevsky D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97–107.
3. Ganem D, Prince AM (2004) Hepatitis B virus infection natural history and clinical consequences. N Engl J Med 350: 1118–1129.
4. Liaw YF, Leung N, Kao JH (2000) For the chronic hepatitis B: a guideline workshop party of the Asian-Pacific Association For The Study Of The Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2000 update. Hepatol Int 2: 263–283.
5. Lok ASF, McMahon BJ (2009) Chronic hepatitis B: update 2009. Hepatology 50: 1–36.
6. European Association For The Study Of The Liver. (2009) Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 50: 227–242.
7. Aggarwala R, Ghoshal UC, Naik SR (2002) Treatment of chronic hepatitis B with interferon-alpha: cost-effectiveness in developing countries. Natl Med J. India 15: 320–3.
8. Ayoob SB, Keefe EB (2008) Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 28: 167–77.
9. Leung N, Peng CY, Hann HW (2009) Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 49: 72–9.
10. Tenney DJ, Rose RE (2009) Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49:1303–14.
11. Tenney DJ, Pokorswky KA, Rose RE (2008) Entecavir at five years show long term maintenance of high genetic barrier to hepatitis B virus resistance. Hepatol Int 2: A80–9.
12. Heathcote EJ, Marcellin P, Buti M (2011) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140:132–43.
13. Patterson SJ, George J, Strasser SI (2011) Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 60: 247–54.
14. Gao L, Huy NT (2013) Tenofovir is more effective than Entecavir for achieving rapid viral suppression in HBsAg-positive chronic hepatitis B patients with high HBV DNA levels. Gastroenterology 144: S–971.
15. Woo G, Tomlinson G, Nishikawa Y (2010) Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 139: 1218–29.
16. Liaw YF, Sheen IS, Lee CM (2011) Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 53: 62–72.
17. Strippayson T, Lueangarum S, Suwannela C (2012) Efficacy and safety of Entecavir versus Tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Gastroenterology 142: S693–S695.
18. Kokol S, Tuna Y, Taner M (2013) Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol 11: 88–94.
19. Dogram UB, Kara B (2012) Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Turk J Gastroenterol 23: 247–52.
20. Kurdoa O, Guzderbit F (2013) Comparison of the efficacy of Tenofovir and Entecavir in chronic hepatitis B patients with high viral load and/or high fibrosis scores at week 48 of therapy. Gastroenterology 140: S930–931.
21. Jayakumar R, Joshi YK, Singh S (2012) Laboratory evaluation of three regimens of treatment of chronic hepatitis B: tenofovir, entecavir and combination of lamivudine and adefovir. J Lab Physicis 4:10.
22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1–12.
23. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–46.
24. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–88.
25. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097.
26. Langley DR, Walsh AW, Baldick CJ (2007) Inhibition of hepatitis B virus polymerase by entecavir. J Virol 81: 3992–4001.
27. Fung J, Lai CL, Seto WK (2011) Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother 66: 2715–25.
28. Buti M, Morillas RM, Prieto M (2010) A viral load reduction > 3 log at 12 week of Entecavir treatment correlated with HBs e serocconversion in HBsAg positive patients. Results from a real-life setting study. Hepatology 52: A409.
29. Lamperico P, Viganò M, Soffredini R (2011) Entecavir monotherapy for nuclease chronic hepatitis B patients from field practice: high efficacy and favorable safety profile over 3 year. Hepatology 54: A1436.
30. Carey I, Nguyen HL, Joe D (2011) Denovo antiviral therapy with nucleos(t)ide analogues in ‘real-life’ patients with chronic hepatitis B infection: comparison of virological response between lamivudine + adefovir, entecavir vs. tenofovir therapy. Hepatology 54: A1396.
31. Ridruejo E, Adefroer R, Cocozzella D (2011) Efficacy of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice. Int J Clin Pract 65: 866–70.
32. Lamperico P, Siffredi R, Viganò M (2011) 2 year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice. Hepatology 54: A1433.
33. Lin CL, Kao JH (2011) The clinical implications of hepatitis B virus genotypes: Recent advances. J Gastroenterol Hepatol 26: 125–30.
34. Fontana RJ (2009) Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49: S183–95.
35. Duarte-Rojo A, Heathcote EJ (2010) Efficacy and safety of tenofovir disoproxil fumarate in patients with chronic hepatitis B. Therap Adv Gastroenterol 3: 107–19.
36. Marcellin P, Buti M, Kravets Z (2010) Continued efficacy and safety through 4 years of tenofovir disoproxil fumarate treatment in HBsAg-negative patients with chronic hepatitis B (study 102): preliminary analysis. Hepatology 52:145A.
37. Heathcote EJ, Marcellin P, Buti M (2010) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140: 132–143.
38. Zoulim F, Locarnini S (2009) Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137: 1593–608.
39. Van Bonnel, de Man RA, Wedemeyer H (2010) Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51: 73–80.
40. Reijnders JG, Deterding K, Petersen J (2010) Antiviral activity of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol 52: 493–500.
41. Suzuki Y, Suzuki F, Kawamura Y (2009) Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance? J Gastroenterol Hepatol 24: 429–35.
42. Karimo Y, Toyota J, Kumada H (2010) Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B. Hepatol Int 4: 414–22.
43. Tenney DJ, Pokorskii KA, Rose RE (2009) Entecavir maintain a high genetic barrier to HBV resistance through 6 years in naive patients. J Hepatol 50: S10.
44. Sleng YJ, Liu JY, Tong SW (2011) Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis. Virol J 8: 393.
45. Petersen J, Buti M (2012) Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogues. Expert Rev Gastroenterol Hepatol 6: 683–93.